Who are the key players in MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market?

April 2022: The sodium-glucose co-transporter-2 (SGLT2) inhibitor, sold as Jardiance, joins Dapagliflozin (sold as Forxiga) as the second medicine of this class to be approved for use in heart failure (HF).
March 2022: A study by the Journal of Medical Economics, Egypt, stated that Dapagliflozin was found to be a highly cost-effective and cost-saving medication when compared to SOC and sacubitril/valsartan, respectively, in the treatment of HF-rEF from the Egyptian healthcare system perspective.

Astrazeneca, Bristol-Myers Squibb, Eli Lilly, Janssen and Astellas are the major companies operating in the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market. Read More

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Companies

Q: How big is the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market?

The MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size is expected to reach USD 165.50 million in 2024 and grow at a CAGR of 9.15% to reach USD 256.40 million by 2029. Read More

Q: What is the current MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size?

In 2024, the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size is expected to reach USD 165.50 million. Read More

Q: What years does this MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market cover, and what was the market size in 2023?

In 2023, the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size was estimated at USD 151.63 million. The report covers the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More